1
|
Zhang X, Zhu B, Guo L, Bakaj I, Rankin M, Ho G, Kauffman J, Lee SP, Norquay L, Macielag M. Optimization of physicochemical properties of pyridone-based EP3 receptor antagonists. Bioorg Med Chem Lett 2021; 47:128172. [PMID: 34091043 DOI: 10.1016/j.bmcl.2021.128172] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2020] [Revised: 05/25/2021] [Accepted: 05/30/2021] [Indexed: 10/21/2022]
Abstract
A novel series of pyridone-based EP3 receptor antagonists was optimized for good physical properties and oral bioavailability in rodents. The lead compounds 3h, 3l and 4d displayed good in vitro profiles, moderate to good metabolic stability and good rodent PK profiles with low clearance, high oral exposure and acceptable half-life.
Collapse
Affiliation(s)
- Xuqing Zhang
- Discovery Sciences, Discovery Chemistry, Janssen Research & Development, LLC, 1400 McKean Road, Box 776, Spring House, PA 19477, United States.
| | - Bin Zhu
- Discovery Sciences, Discovery Chemistry, Janssen Research & Development, LLC, 1400 McKean Road, Box 776, Spring House, PA 19477, United States
| | - Lili Guo
- Cardiovascular and Metabolism Research, Janssen Research & Development, LLC, 1400 McKean Road, Box 776, Spring House, PA 19477, United States
| | - Ivona Bakaj
- Cardiovascular and Metabolism Research, Janssen Research & Development, LLC, 1400 McKean Road, Box 776, Spring House, PA 19477, United States
| | - Matthew Rankin
- Cardiovascular and Metabolism Research, Janssen Research & Development, LLC, 1400 McKean Road, Box 776, Spring House, PA 19477, United States
| | - George Ho
- Cardiovascular and Metabolism Research, Janssen Research & Development, LLC, 1400 McKean Road, Box 776, Spring House, PA 19477, United States
| | - Jack Kauffman
- Discovery Sciences, Lead Discovery, Janssen Research & Development, LLC, 1400 McKean Road, Box 776, Spring House, PA 19477, United States
| | - Seunghun P Lee
- Cardiovascular and Metabolism Research, Janssen Research & Development, LLC, 1400 McKean Road, Box 776, Spring House, PA 19477, United States
| | - Lisa Norquay
- Cardiovascular and Metabolism Research, Janssen Research & Development, LLC, 1400 McKean Road, Box 776, Spring House, PA 19477, United States
| | - Mark Macielag
- Discovery Sciences, Discovery Chemistry, Janssen Research & Development, LLC, 1400 McKean Road, Box 776, Spring House, PA 19477, United States
| |
Collapse
|
2
|
Zhang X, Zhu B, Guo L, Bakaj I, Rankin M, Ho G, Kauffman J, Lee SP, Norquay L, Macielag MJ. Discovery of a Novel Series of Pyridone-Based EP3 Antagonists for the Treatment of Type 2 Diabetes. ACS Med Chem Lett 2021; 12:451-458. [PMID: 33738072 DOI: 10.1021/acsmedchemlett.0c00667] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2020] [Accepted: 02/23/2021] [Indexed: 12/31/2022] Open
Abstract
A novel series of pyridones were discovered as potent EP3 antagonists. Optimization guided by EP3 binding and functional assays as well as by eADME and PK profiling led to multiple compounds with good physical properties, excellent oral bioavailability, and a clean in vitro safety profile. Compound 13 was identified as a lead compound as evidenced by the reversal of sulprostone-induced suppression of glucose-stimulated insulin secretion in INS 1E β-cells in vitro and in a rat ivGTT model in vivo. A glutathione adduction liability was eliminated by replacing the naphthalene of structure 13 with the indazole ring of structure 43.
Collapse
|
3
|
Lee ECY, Futatsugi K, Arcari JT, Bahnck K, Coffey SB, Derksen DR, Kalgutkar AS, Loria PM, Sharma R. Optimization of amide-based EP3 receptor antagonists. Bioorg Med Chem Lett 2016; 26:2670-5. [PMID: 27107947 DOI: 10.1016/j.bmcl.2016.04.009] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2016] [Revised: 04/04/2016] [Accepted: 04/05/2016] [Indexed: 11/17/2022]
Abstract
Prostaglandin E receptor subtype 3 (EP3) antagonism may treat a variety of symptoms from inflammation to cardiovascular and metabolic diseases. Previously, most EP3 antagonists were large acidic ligands that mimic the substrate, prostaglandin E2 (PGE2). This manuscript describes the optimization of a neutral small molecule amide series with improved lipophilic efficiency (LipE) also known as lipophilic ligand efficiency (LLE) ((a) Nat. Rev. Drug Disc.2007, 6, 881; (b) Annu. Rep. Med. Chem.2010, 45, 380).
Collapse
Affiliation(s)
- Esther C Y Lee
- Worldwide Medicinal Chemistry, Pfizer Worldwide Research & Development, Cambridge, MA 02139, United States.
| | - Kentaro Futatsugi
- Worldwide Medicinal Chemistry, Pfizer Worldwide Research & Development, Cambridge, MA 02139, United States
| | - Joel T Arcari
- Worldwide Medicinal Chemistry, Pfizer Worldwide Research & Development, Groton, CT 06340, United States
| | - Kevin Bahnck
- Worldwide Medicinal Chemistry, Pfizer Worldwide Research & Development, Groton, CT 06340, United States
| | - Steven B Coffey
- Worldwide Medicinal Chemistry, Pfizer Worldwide Research & Development, Groton, CT 06340, United States
| | - David R Derksen
- Pharmacokinetics, Dynamics, and Metabolism, Pfizer Worldwide Research & Development, Groton, CT 06340, United States
| | - Amit S Kalgutkar
- Pharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Cambridge, MA 02139, United States
| | - Paula M Loria
- Pharmacokinetics, Dynamics, and Metabolism, Pfizer Worldwide Research & Development, Groton, CT 06340, United States
| | - Raman Sharma
- Pharmacokinetics, Dynamics, and Metabolism, Pfizer Worldwide Research & Development, Groton, CT 06340, United States
| |
Collapse
|
5
|
Chen T, Luo Y, Sheng L, Li J, Hu Y, Lu W. Synthesis and in vitro cytotoxic evaluation of novel N-(3,4,5-trimethoxyphenyl)pyridin-2(1H)-one derivatives. Mol Divers 2013; 17:435-44. [PMID: 23612851 DOI: 10.1007/s11030-013-9442-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2012] [Accepted: 04/04/2013] [Indexed: 10/26/2022]
Abstract
A series of novel [Formula: see text]-(3,4,5-trimethoxyphenyl)pyridin-2([Formula: see text])-one derivatives were designed, synthesized, and evaluated for their in vitro cytotoxicity against human colon cancer cells HCT-116. The key steps involved consecutive Chan-Lam- and Buchwald-Hartwig couplings. Most of these C-6 substituted pyridone derivatives showed moderate antiproliferative activity. The preliminary SAR indicated that the conformationally restricted pyridones exhibited more potent cytotoxicity than the flexible counterparts. In addition, cell cycle analysis of the selected compounds 4b and e showed a G2/M arrest, suggesting a possible antitubulin mechanism for these novel pyridone derivatives.
Collapse
Affiliation(s)
- Taijie Chen
- Department of Chemistry, East China Normal University, 3663 North Zhongshan Road, Shanghai, 200062, China
| | | | | | | | | | | |
Collapse
|